Top

Published in:

01-01-2012 | Review

The roles of thrombin and protease-activated receptors in inflammation

Authors: Liang Ma, Anthony Dorling

Published in: Seminars in Immunopathology | Issue 1/2012

Abstract

Inflammation and coagulation constitute two host defence systems with complementary physiological roles in limiting tissue damage, restoring homeostasis and eliminating invading pathogens, functions reliant on effective regulation of both processes at a variety of levels. Dysfunctional activation or regulation of either pathway may lead to pathology and contribute to human diseases as diverse as myocardial infarction and septic shock. The serine protease thrombin, a key protein in the coagulation pathway, can activate cellular signalling directly via proteolytic cleavage of the N-terminal domain of a family of G protein-coupled receptors or indirectly through the generation of molecules such as activated protein C. These events transmit signals to many cell types and can elicit the production of various pro-inflammatory mediators such as cytokines, chemokines and growth factors, thereby influencing cell activation, differentiation, survival and migration. This review discusses recent progress in understanding how thrombin and protease-activated receptors influence biological processes, highlighting the detrimental and protective cellular effects of thrombin and its signalling pathways.

Cirino G, Napoli C, Bucci M, Cicala C (2000) Inflammation-coagulation network: are serine protease receptors the knot? Trends Pharmacol Sci 21:170–172PubMedCrossRef

Coughlin SR (2000) Thrombin signalling and protease-activated receptors. Nature 407:258–264PubMedCrossRef

Coughlin SR (2001) Protease-activated receptors in vascular biology. Thromb Haemost 86:298–307PubMed

Macfarlane SR, Seatter MJ, Kanke T, Hunter GD, Plevin R (2001) Proteinase-activated receptors. Pharmacol Rev 53:245–282PubMed

Martorell L, Martinez-Gonzalez J, Rodriguez C, Gentile M, Calvayrac O, Badimon L (2008) Thrombin and protease-activated receptors (PARS) in atherothrombosis. Thromb Haemost 99:305–315PubMed

Santilli F, Davi G (2009) Thrombin as a common downstream target blocking both platelet and monocyte activation. Thromb Haemost 101:220–221PubMed

Nierodzik ML, Kajumo F, Karpatkin S (1992) Effect of thrombin treatment of tumor cells on adhesion of tumor cells to platelets in vitro and tumor metastasis in vivo. Cancer Res 52:3267–3272PubMed

Kaplanski G, Marin V, Fabrigoule M, Boulay V, Benoliel AM, Bongrand P et al (1998) Thrombin-activated human endothelial cells support monocyte adhesion in vitro following expression of intercellular adhesion molecule-1 (ICAM-1; CD54) and vascular cell adhesion molecule-1 (VCAM-1; CD106). Blood 92:1259–1267PubMed

Ossovskaya VS, Bunnett NW (2004) Protease-activated receptors: contribution to physiology and disease. Physiol Rev 84:579–621PubMedCrossRef

10.

Coughlin SR (2005) Protease-activated receptors in hemostasis, thrombosis and vascular biology. J Thromb Haemost 3:1800–1814PubMedCrossRef

11.

Steinhoff M, Buddenkotte J, Shpacovitch V, Rattenholl A, Moormann C, Vergnolle N et al (2005) Proteinase-activated receptors: transducers of proteinase-mediated signalling in inflammation and immune response. Endocr Rev 26:1–43PubMedCrossRef

12.

Steinhoff M, Corvera CU, Thoma MS, Kong W, McAlpine BE, Caughey GH et al (1999) Proteinase-activated receptor-2 in human skin: tissue distribution and activation of keratinocytes by mast cell tryptase. Exp Dermatol 8:282–294PubMedCrossRef

13.

Molino M, Barnathan ES, Numerof R, Clark J, Dreyer M, Cumashi A et al (1997) Interactions of mast cell tryptase with thrombin receptors and PAR-2. J Biol Chem 272:4043–4049PubMedCrossRef

14.

Nystedt S, Emilsson K, Larsson AK, Strombeck B, Sundelin J (1995) Molecular cloning and functional expression of the gene encoding the human proteinase-activated receptor 2. Eur J Biochem 232:84–89PubMedCrossRef

15.

Camerer E, Huang W, Coughlin SR (2000) Tissue factor- and factor X-dependent activation of protease-activated receptor 2 by factor VIIa. Proc Natl Acad Sci U S A 97:5255–5260PubMedCrossRef

16.

Warr TA, Rao LV, Rapaport SI (1990) Disseminated intravascular coagulation in rabbits induced by administration of endotoxin or tissue factor: effect of anti-tissue factor antibodies and measurement of plasma extrinsic pathway inhibitor activity. Blood 75:1481–1489PubMed

17.

Akahane K, Okamoto K, Kikuchi M, Todoroki H, Higure A, Ohuchida T et al (2001) Inhibition of factor Xa suppresses the expression of tissue factor in human monocytes and lipopolysaccharide-induced endotoxemia in rats. Surgery 130:809–818PubMedCrossRef

18.

Creasey AA, Chang AC, Feigen L, Wun TC, Taylor FB Jr, Hinshaw LB (1993) Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J Clin Invest 91:2850–2860PubMedCrossRef

19.

Levi M, ten Cate H, Bauer KA, van der Poll T, Edgington TS, Buller HR et al (1994) Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees. J Clin Invest 93:114–120PubMedCrossRef

20.

Dackiw AP, McGilvray ID, Woodside M, Nathens AB, Marshall JC, Rotstein OD (1996) Prevention of endotoxin-induced mortality by antitissue factor immunization. Arch Surg 131:1273–1278, discussion 1278–1279PubMedCrossRef

21.

Pawlinski R, Pedersen B, Schabbauer G, Tencati M, Holscher T, Boisvert W et al (2004) Role of tissue factor and protease-activated receptors in a mouse model of endotoxemia. Blood 103:1342–1347PubMedCrossRef

22.

Cunningham MA, Rondeau E, Chen X, Coughlin SR, Holdsworth SR, Tipping PG (2000) Protease-activated receptor 1 mediates thrombin-dependent, cell-mediated renal inflammation in crescentic glomerulonephritis. J Exp Med 191:455–462PubMedCrossRef

23.

Howell DC, Johns RH, Lasky JA, Shan B, Scotton CJ, Laurent GJ et al (2005) Absence of proteinase-activated receptor-1 signalling affords protection from bleomycin-induced lung inflammation and fibrosis. Am J Pathol 166:1353–1365PubMedCrossRef

24.

Shimizu S, Shimizu T, Morser J, Kobayashi T, Yamaguchi A, Qin L et al (2008) Role of the coagulation system in allergic inflammation in the upper airways. Clin Immunol 129:365–371PubMedCrossRef

25.

Strande JL, Phillips SA (2009) Thrombin increases inflammatory cytokine and angiogenic growth factor secretion in human adipose cells in vitro. J Inflamm (Lond) 6:4CrossRef

26.

Vera PL, Wolfe TE, Braley AE, Meyer-Siegler KL (2010) Thrombin induces macrophage migration inhibitory factor release and upregulation in urothelium: a possible contribution to bladder inflammation. PLoS One 5:e15904PubMedCrossRef

27.

Minami T, Sugiyama A, Wu SQ, Abid R, Kodama T, Aird WC (2004) Thrombin and phenotypic modulation of the endothelium. Arterioscler Thromb Vasc Biol 24:41–53PubMedCrossRef

28.

Rahman A, Fazal F (2009) Hug tightly and say goodbye: role of endothelial ICAM-1 in leukocyte transmigration. Antioxid Redox Signal 11:823–839PubMedCrossRef

29.

Delekta PC, Apel IJ, Gu S, Siu K, Hattori Y, McAllister-Lucas LM et al (2010) Thrombin-dependent NF-{kappa}B activation and monocyte/endothelial adhesion are mediated by the CARMA3.Bcl10.MALT1 signalosome. J Biol Chem 285:41432–41442PubMedCrossRef

30.

Popovic M, Paskas S, Zivkovic M, Burysek L, Laumonnier Y (2010) Human cytomegalovirus increases HUVEC sensitivity to thrombin and modulates expression of thrombin receptors. J Thromb Thrombolysis 30:164–171PubMedCrossRef

31.

Chung SW, Park JW, Lee SA, Eo SK, Kim K (2010) Thrombin promotes proinflammatory phenotype in human vascular smooth muscle cell. Biochem Biophys Res Commun 396:748–754PubMedCrossRef

32.

Kastl SP, Speidl WS, Katsaros KM, Kaun C, Rega G, Assadian A et al (2009) Thrombin induces the expression of oncostatin M via AP-1 activation in human macrophages: a link between coagulation and inflammation. Blood 114:2812–2818PubMedCrossRef

33.

Bae JS, Kim YU, Park MK, Rezaie AR (2009) Concentration dependent dual effect of thrombin in endothelial cells via PAR-1 and PI3 kinase. J Cell Physiol 219:744–751PubMedCrossRef

34.

Bae JS, Yang L, Manithody C, Rezaie AR (2007) The ligand occupancy of endothelial protein c receptor switches the protease-activated receptor 1-dependent signalling specificity of thrombin from a permeability-enhancing to a barrier-protective response in endothelial cells. Blood 110:3909–3916PubMedCrossRef

35.

Bae JS, Rezaie AR (2008) Protease activated receptor 1 (PAR-1) activation by thrombin is protective in human pulmonary artery endothelial cells if endothelial protein c receptor is occupied by its natural ligand. Thromb Haemost 100:101–109PubMed

36.

Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A et al (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344:699–709PubMedCrossRef

37.

Abraham E, Reinhart K, Opal S, Demeyer I, Doig C, Rodriguez AL et al (2003) Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 290:238–247PubMedCrossRef

38.

Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I et al (2001) Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 286:1869–1878PubMedCrossRef

39.

Ahamed J, Belting M, Ruf W (2005) Regulation of tissue factor-induced signalling by endogenous and recombinant tissue factor pathway inhibitor 1. Blood 105:2384–2391PubMedCrossRef

40.

Rosen H, Goetzl EJ (2005) Sphingosine 1-phosphate and its receptors: an autocrine and paracrine network. Nat Rev Immunol 5:560–570PubMedCrossRef

41.

Singleton PA, Moreno-Vinasco L, Sammani S, Wanderling SL, Moss J, Garcia JG (2007) Attenuation of vascular permeability by methylnaltrexone: role of mOP-R and S1P3 transactivation. Am J Respir Cell Mol Biol 37:222–231PubMedCrossRef

42.

Feistritzer C, Riewald M (2005) Endothelial barrier protection by activated protein c through PAR1-dependent sphingosine 1-phosphate receptor-1 crossactivation. Blood 105:3178–3184PubMedCrossRef

43.

Singleton PA, Dudek SM, Ma SF, Garcia JG (2006) Transactivation of sphingosine 1-phosphate receptors is essential for vascular barrier regulation. Novel role for hyaluronan and CD44 receptor family. J Biol Chem 281:34381–34393PubMedCrossRef

44.

Niessen F, Schaffner F, Furlan-Freguia C, Pawlinski R, Bhattacharjee G, Chun J et al (2008) Dendritic cell PAR1-S1P3 signalling couples coagulation and inflammation. Nature 452:654–658PubMedCrossRef

45.

Esmon CT (2006) Inflammation and the activated protein C anticoagulant pathway. Semin Thromb Hemost 32(Suppl 1):49–60PubMedCrossRef

46.

Dahlback B, Villoutreix BO (2005) Regulation of blood coagulation by the protein C anticoagulant pathway: novel insights into structure-function relationships and molecular recognition. Arterioscler Thromb Vasc Biol 25:1311–1320PubMedCrossRef

47.

Mosnier LO, Zlokovic BV, Griffin JH (2007) The cytoprotective protein C pathway. Blood 109:3161–3172PubMedCrossRef

48.

Kerschen EJ, Fernandez JA, Cooley BC, Yang XV, Sood R, Mosnier LO et al (2007) Endotoxemia and sepsis mortality reduction by non-anticoagulant activated protein C. J Exp Med 204:2439–2448PubMedCrossRef

49.

Niessen F, Furlan-Freguia C, Fernandez JA, Mosnier LO, Castellino FJ, Weiler H et al (2009) Endogenous EPCR/APC-PAR1 signalling prevents inflammation-induced vascular leakage and lethality. Blood 113:2859–2866PubMedCrossRef

50.

Schuepbach RA, Feistritzer C, Fernandez JA, Griffin JH, Riewald M (2009) Protection of vascular barrier integrity by activated protein C in murine models depends on protease-activated receptor-1. Thromb Haemost 101:724–733PubMed

51.

Chen D, Carpenter A, Abrahams J, Chambers RC, Lechler RI, McVey JH et al (2008) Protease-activated receptor 1 activation is necessary for monocyte chemoattractant protein 1-dependent leukocyte recruitment in vivo. J Exp Med 205:1739–1746PubMedCrossRef

52.

Hamill CE, Goldshmidt A, Nicole O, McKeon RJ, Brat DJ, Traynelis SF (2005) Special lecture: glial reactivity after damage: implications for scar formation and neuronal recovery. Clin Neurosurg 52:29–44PubMed

53.

Henrich-Noack P, Riek-Burchardt M, Baldauf K, Reiser G, Reymann KG (2006) Focal ischemia induces expression of protease-activated receptor1 (PAR1) and PAR3 on microglia and enhances PAR4 labeling in the penumbra. Brain Res 1070:232–241PubMedCrossRef

54.

Ishida Y, Nagai A, Kobayashi S, Kim SU (2006) Upregulation of protease-activated receptor-1 in astrocytes in Parkinson disease: astrocyte-mediated neuroprotection through increased levels of glutathione peroxidase. J Neuropathol Exp Neurol 65:66–77PubMedCrossRef

55.

Fabrizi C, Pompili E, Panetta B, Nori SL, Fumagalli L (2009) Protease-activated receptor-1 regulates cytokine production and induces the suppressor of cytokine signalling-3 in microglia. Int J Mol Med 24:367–371PubMedCrossRef

56.

Hamill CE, Mannaioni G, Lyuboslavsky P, Sastre AA, Traynelis SF (2009) Protease-activated receptor 1-dependent neuronal damage involves NMDA receptor function. Exp Neurol 217:136–146PubMedCrossRef

57.

Ikehara O, Hayashi H, Watanabe Y, Yamamoto H, Mochizuki T, Hoshino M et al (2010) Proteinase-activated receptors-1 and 2 induce electrogenic Cl⁻ secretion in the mouse cecum by distinct mechanisms. Am J Physiol Gastrointest Liver Physiol 299:G115–G125PubMedCrossRef

58.

Wang H, Moreau F, Hirota CL, MacNaughton WK (2010) Proteinase-activated receptors induce interleukin-8 expression by intestinal epithelial cells through ERK/RSK90 activation and histone acetylation. FASEB J 24:1971–1980PubMedCrossRef

59.

Luyendyk JP, Sullivan BP, Guo GL, Wang R (2010) Tissue factor-deficiency and protease activated receptor-1-deficiency reduce inflammation elicited by diet-induced steatohepatitis in mice. Am J Pathol 176:177–186PubMedCrossRef

60.

Wee JL, Chionh YT, Ng GZ, Harbour SN, Allison C, Pagel CN et al (2010) Protease-activated receptor-1 down-regulates the murine inflammatory and humoral response to Helicobacter pylori. Gastroenterology 138:573–582PubMedCrossRef

61.

Sawicki G, Salas E, Murat J, Miszta-Lane H, Radomski MW (1997) Release of gelatinase A during platelet activation mediates aggregation. Nature 386:616–619PubMedCrossRef

62.

Kazes I, Elalamy I, Sraer JD, Hatmi M, Nguyen G (2000) Platelet release of trimolecular complex components MT1-MMP/TIMP2/MMP2: Involvement in MMP2 activation and platelet aggregation. Blood 96:3064–3069PubMed

63.

Galt SW, Lindemann S, Allen L, Medd DJ, Falk JM, McIntyre TM et al (2002) Outside-in signals delivered by matrix metalloproteinase-1 regulate platelet function. Circ Res 90:1093–1099PubMedCrossRef

64.

Trivedi V, Boire A, Tchernychev B, Kaneider NC, Leger AJ, O'Callaghan K et al (2009) Platelet matrix metalloprotease-1 mediates thrombogenesis by activating PAR1 at a cryptic ligand site. Cell 137:332–343PubMedCrossRef

65.

Lee EJ, Woo MS, Moon PG, Baek MC, Choi IY, Kim WK et al (2010) Alpha-synuclein activates microglia by inducing the expressions of matrix metalloproteinases and the subsequent activation of protease-activated receptor-1. J Immunol 185:615–623PubMedCrossRef

66.

Mao Y, Zhang M, Tuma RF, Kunapuli SP (2010) Deficiency of PAR4 attenuates cerebral ischemia/reperfusion injury in mice. J Cereb Blood Flow Metab 30:1044–1052PubMedCrossRef

67.

Russell FA, Veldhoen VE, Tchitchkan D, McDougall JJ (2010) Proteinase-activated receptor-4 (PAR4) activation leads to sensitization of rat joint primary afferents via a bradykinin B2 receptor-dependent mechanism. J Neurophysiol 103:155–163PubMedCrossRef

68.

Dabek M, Ferrier L, Roka R, Gecse K, Annahazi A, Moreau J et al (2009) Luminal cathepsin g and protease-activated receptor 4: a duet involved in alterations of the colonic epithelial barrier in ulcerative colitis. Am J Pathol 175:207–214PubMedCrossRef

69.

Megyeri M, Mako V, Beinrohr L, Doleschall Z, Prohaszka Z, Cervenak L et al (2009) Complement protease MASP-1 activates human endothelial cells: PAR4 activation is a link between complement and endothelial function. J Immunol 183:3409–3416PubMedCrossRef

70.

Wilson BJ, Harada R, LeDuy L, Hollenberg MD, Nepveu A (2009) CUX1 transcription factor is a downstream effector of the proteinase-activated receptor 2 (PAR2). J Biol Chem 284:36–45PubMedCrossRef

71.

Jesmin S, Gando S, Zaedi S, Prodhan SH, Sawamura A, Miyauchi T et al (2009) Protease-activated receptor 2 blocking peptide counteracts endotoxin-induced inflammation and coagulation and ameliorates renal fibrin deposition in a rat model of acute renal failure. Shock 32:626–632PubMedCrossRef

72.

Rallabhandi P, Nhu QM, Toshchakov VY, Piao W, Medvedev AE, Hollenberg MD et al (2008) Analysis of proteinase-activated receptor 2 and TLR4 signal transduction: a novel paradigm for receptor cooperativity. J Biol Chem 283:24314–24325PubMedCrossRef

73.

Nhu QM, Shirey K, Teijaro JR, Farber DL, Netzel-Arnett S, Antalis TM et al (2010) Novel signalling interactions between proteinase-activated receptor 2 and toll-like receptors in vitro and in vivo. Mucosal Immunol 3:29–39PubMedCrossRef

74.

McIntosh K, Cunningham MR, Cadalbert L, Lockhart J, Boyd G, Ferrell WR et al (2010) Proteinase-activated receptor-2 mediated inhibition of TNFalpha-stimulated JNK activation—a novel paradigm for G(q/11) linked GPCRS. Cell Signal 22:265–273PubMedCrossRef

75.

Li R, Rohatgi T, Hanck T, Reiser G (2009) Alpha A-crystallin and alpha B-crystallin, newly identified interaction proteins of protease-activated receptor-2, rescue astrocytes from C2-ceramide- and staurosporine-induced cell death. J Neurochem 110:1433–1444PubMedCrossRef

Title: The roles of thrombin and protease-activated receptors in inflammation
Authors: Liang Ma
Anthony Dorling
Publication date: 01-01-2012
Publisher: Springer-Verlag
Published in: Seminars in Immunopathology / Issue 1/2012
Print ISSN: 1863-2297
Electronic ISSN: 1863-2300
DOI: https://doi.org/10.1007/s00281-011-0281-9

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2012

Sphingosine 1-phosphate in coagulation and inflammation

The procoagulant and proinflammatory plasma contact system

Endothelium—role in regulation of coagulation and inflammation

Fibrinogen as a key regulator of inflammation in disease

Systemic versus localized coagulation activation contributing to organ failure in critically ill patients

Coagulation and inflammation—close allies in health and disease

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials